Skip to main content

Experience fast bleed

control with NovoSeven® RT.

The faster you can infuse treatment, the sooner it can start to work. NovoSeven® RT is quick to mix and fast to infuse.

Experience fast bleed control with NovoSeven® RT.

The faster you can infuse treatment, the sooner it can start to work. NovoSeven® RT is quick to mix and fast to infuse.

Experience proven bleed control.

Data from a randomized, double-blind study of patients with hemophilia A and B with and without inhibitors.

Pie Charts: 86% effective in controlling muscle bleeds and 91% effective in controlling joint bleeds

Also proven effective in the adept™2 study, one of the largest clinical trials conducted in patients with hemophilia with inhibitors.

Pie Chart: 93% comparable efficacy seen in joint, target joint, mucocutaneous, muscle, and other bleeding episodes

Joint, target joint, skin, and mucous membrane, muscle, and other bleeding episodes (n=227 bleeding episodes)


Room temperature stable and travel ready.

NovoSeven® RT comes in compact packaging, and is room temperature stable up to 77°F, so you can be on the go.a  

aNovoSeven® RT should be stored between 36°F and 77°F.
For complete storage information, please see Prescribing Information.


Quick to mix.b

NovoSeven® RT with MixPro® makes mixing a dose fast. The prefilled syringe means no extra steps to fill a syringe with diluent.
 

After mixing, NovoSeven® RT may be stored at room temperature in the vial for up to 3 hours.

bCompared to mixing using histidine vials.


Fast to infuse.

Faster infusion means NovoSeven® RT gets to work stopping bleeds more quickly.
 

  • NovoSeven® RT is up to 18x faster to infuse than FEIBAc-e 
  • Infusing takes 2 to 5 minutes


c
Administer as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.
d
Individual doses are compared and based on an 88-kg (194-lb) person.
ePatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute.

 


Fast bleed control.

Helps control joint bleeds in as few as 5 hours with a median of 2 doses.f 

  • NovoSeven® RT can be redosed every 2 hours,c which lets you dose as needed to get bleeds under control fast
  • Your hemophilia treatment center (HTC) and your doctor will help you decide which dosing schedule is best for you

 

fBased on individual dosage for joint bleeds in people with hemophilia A or B with and without inhibitors.


Established safety profile that comes from experience.g

In clinical trials of NovoSeven® RT, a low rate of blood clots (0.2%) were reported.h And NovoSeven® RT is made without any human blood or plasma. It’s the only FDA-approved recombinant bypassing agent for hemophilia with inhibitors. Recombinant manufacturing minimizes the possibility of viral contamination.


g
Compassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.
hFor people with hemophilia A or B with inhibitors.

Icon: Microscope

NovoSeven® RT has only 1 main component.

Main component of novosevenrt vs
Main component of novosevenrt vs

What if I need surgery or a procedure?

We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT is approved by the FDA for treating people with hemophilia A or B with inhibitors during and after surgery and procedures.

In fact, in a clinical trial, NovoSeven® RT was proven to effectively control bleeds throughout the surgical process. Here are the results:

Talk with your doctor for more information on controlling bleeds during and after surgery or procedures.

What about surgery and procedures?

Approved for surgical use and procedures for patients with hemophilia A or B with inhibitors.

Hear a patient's story.

Meet Justin. NovoSeven® RT fits in when he's living life on the go.

Meet Justin thumbnail
Meet Justin/Meet Chase videos

Hear from people who

share your experience.


Illustration: Removing syringe cap

New to treatment? It’s

easy to get started.


Icon: 5-step purification process of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

Recombinant manufacturing

minimizes risk of viral contamination

Selected Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
  • You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven® RT?

  • Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
    • congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
    • are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
    • history of heart or blood vessel diseases
  • Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven® RT?

  • The most common and serious side effects are blood clots
  • Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information